
hplatt@gmail.com

+1-732-485-9222

103 Pendulum Way
North Wales, PA 19454

Heather L. Platt, M.D.

Infectious Disease trained physician scientist with broad clinical research experience in the pharmaceutical industry leading cross-functional teams to engage in strategic discussion and support clinical development. Collaborative approach to leading the focused execution of clinical studies with quality, from proof of concept to regulatory submissions, and lifecycle management.

EMPLOYMENT

Merck & Co, Inc. 7/2014-present

Clinical Research, Infectious Diseases & Vaccines
351 Sumneytown Pike
P.O. Box 1000
North Wales, PA 19454-1099

Scientific Associate Vice President, Clinical Research Vaccines 2024-present

- Oversight of multiple vaccine franchises in the vaccine portfolio
- Leading teams to deliver on clinical development of respiratory vaccines to address unmet medical need in support of public health
- Promotion of cross-functional teams with responsibility for eight direct reports
- Chair of review committees to deliver protocols and enable quality based trial execution
- Workstream lead to implement data driven, efficient solutions in a highly regulated environment

Executive Director of Clinical Research, Vaccines 2021-2024

- Product Development Team Lead steering cross-functional teams to support pipeline and late-stage products through development including early-stage clinical studies, late-stage clinical studies, post-marketing commitments, and commercialization;
- Collaborate with key stakeholders to design protocols and analysis plans, conduct in-life medical monitoring, interpret and communicate study results for clinical study reports, and timely publication;

- Engage with regulatory agencies from IND through BLA/MAA submission;
- Cultivate an inclusive team environment through active listening, engagement, and trust;
- Support career development of direct reports including identifying internal and external training and learning opportunities;
- Experience across small molecule and biologics, including live virus and conjugate vaccines.

Sr. Principal Scientist, Clinical Research

2017-2021

- Led cross-functional teams to execute clinical studies with quality and efficiency, including study design, protocol authoring, study execution, and clinical study report delivery
- Review of protocols and processes to ensure consistent implementation
- Medical monitoring subject matter expert
- Presentation of clinical data at scientific congresses

Principal Scientist, Clinical Research

2014-2017

- Clinical Director in late-stage clinical development in Infectious Disease and Vaccines, responsible for:
- Study design and authoring protocols,
- Medical monitoring of safety and efficacy endpoints,
- Analysis of clinical data and summarization of impact and conclusions,
- Production of clinical study reports to support submissions,
- Development of manuscripts for publication

EDUCATION

Infectious Disease Fellowship	7/2012-6/2014
New York Presbyterian / Columbia University Medical Center 630 West 168 th St. P&S Box 82 New York, NY 10032	
Chief Resident	7/2011-6/2012
Internal Medicine Residency	7/2008-6/2011
Rutgers/Robert Wood Johnson Medical School 1 Robert Wood Johnson Place, MEB 486 New Brunswick, NJ 08903	
Doctor of Medicine	8/2004-5/2008

Rutgers - New Jersey Medical School (previously
UMDNJ) 185 South Orange Ave.
Newark, NJ 07103

Post-Baccalaureate Certificate; Pre-Medical Studies 9/2002-12/2003

University College, Rutgers University
New Brunswick, NJ 08901

Bachelor of Science cum laude in Theatre Arts and Broadcast 8/1992-5/1996

Communication, Carl S. Ell Scholar

Northeastern University

Boston, MA 02115

LICENSURE, CERTIFICATION, APPOINTMENTS

New Jersey State License: 25MA08859600

National Provider Identifier: 1922309350

Diplomate of the American Board of Internal Medicine 2011 – 2021

Diplomate of the American Board of Internal Medicine, Infectious Disease, 2017-2027

Instructor, Department of Medicine, 7/2011-8/2012

UMDNJ-Robert Wood Johnson Medical School

New Brunswick, NJ 08903

Robert Wood Johnson University Hospital, 8/2011-8/2012

1 Robert Wood Johnson Place

New Brunswick, NJ 08903

University Medical Center at Princeton, 7/2011-8/2012

253 Witherspoon St.

Princeton, NJ 08540

HONORS AND AWARDS

Residency

PGY 3 Award for Humanism and Professionalism 2010-2011 PGY 2 Outstanding Resident
Award, 2009-2010

Robert S. Pinals Humanism and Professionalism Award, 2008-2009

Medical School

Alpha Omega Alpha, New Jersey Beta Chapter 2008

Drs. Milton & Rose Prystowsky Award for Overall Excellence In Patient Care, 2008

Arnold P. Gold Humanism Scholar, 2008

New Jersey Medical Women's Association Hans-Krenle Scholarship, 2007 NJMS Alumni
Association Endowed Scholarship, 2007

NJMS Alumni Association Edna and Howard Alger Memorial Endowed Scholarship, 2006

Union County Medical Society Alliance Scholarship 2006 NJMS Alumni Association Class of
1962 Scholarship, 2005

COMMITTEES AND SERVICE ACTIVITIES

Service on Medical School Committees

Clinical Curriculum Subcommittee, 2006-2008

Stuart D. Cook Master Educator Guild Selection Committee, 2007 Transition 2 Planning Committee 2007

Student Health Advocates for Resources and Education (SHARE), Assistant Director, 2005-2006

Service on Graduate School Committees

Internal Medicine Humanism and Professionalism Committee, 2009 Gold Humanism Task Force 2008, Robert Wood Johnson Medical School

Service on UMDNJ Affiliated Hospital Committees

Graduate Medical Education Committee, Chairperson, Resident Subcommittee, 2009-2011

Service To The Community

AIDS Resource Foundation for Children, Volunteer 2004 - 2006

Delta Sigma Theta Community Arts Festival, Mural Artist 2002, 2003

Tri-State Wheelchair Games, Volunteer 2002

Carteret Skate Park Mural, Project Coordinator and Artist 2001

Carteret Health and Wellness Fair, Volunteer 2001

Educational Activities

Fellowship

- Teaching residents and medical students on Infectious Disease Rotation
- Didactic presentations for small group learning

Residency

- As chief resident, led daily noon conference with emphasis on evidence-based medicine
- Taught small-group clinical skills sessions for junior medical students

PUBLICATIONS

Chapter in Book

1. Lee J, Kalmar K, Holland BK, Platt H. Associated Topics in Physical Medicine and Rehabilitation: Biostatistics. In Cuccurullo S. (Ed). Physical Medicine and Rehabilitation Board Review (2nd ed). New York: Demos Medical Publishing; 2009.

Refereed Original Articles in Journal

1. Xu W, Antonello J, Nguyen J, Ma C, Cheng YW, Marullo K, Nolan K, Buchwald UK, Platt HL, Bonhomme M, LaFon DC, Burton RL, Nahm MH, Helmy R. Low Intrinsic Killing Activity and no Impact of Its Positivity on Phase 3 Pneumococcal Vaccine Adult Studies. J Infect Dis. 2026 Jan 17;233(1):101-111. doi: 10.1093/infdis/jiaf427. PMID: 40796175.

2. Li J, Platt HL, Hu W, Xu W, Chapman TJ, Nolan KM, Hartzel J, Buchwald UK. Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116. *Commun Med (Lond)*. 2025 Oct 29;5(1):443. doi: 10.1038/s43856-025-01106-z. PMID: 41162647; PMCID: PMC12572306.
3. Joshi R, Ayele HT, Johnson KD, Velentgas P, Platt H, Saddier P. Anticipated impact of novel adult-specific pneumococcal conjugate vaccine. *Vaccine*. 2025 Apr 19;53:127080. doi: 10.1016/j.vaccine.2025.127080. Epub 2025 Apr 13. PMID: 40220708.
4. Jotterand V, Jagannath V, Diaz AA, Velez JD, Letica A, Perez SN, Clark R, Caraco Y, Degen O, Park KH, Ünal S, Wittke F, Hurtado K, Churchill C, Zhang Y, Fernsler D, Li J, Buchwald UK, Platt H. A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥ 50 Years of Age (STRIDE-10). *Vaccines (Basel)*. 2025 Mar 22;13(4):341. doi: 10.3390/vaccines13040341. PMID: 40333240; PMCID: PMC12031205.
5. Pathirana J, Ramgopal M, Martin C, et al. Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial. *Lancet HIV*. 2025;12(10):e679-e690. doi:10.1016/S2352-3018(25)00165-1
6. Kishino H, Inoue S, Matsuoka O, Yagi M, Igarashi R, Oshima N, Sawata M, Platt HL. A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥ 65 years of age. *Vaccine*. 2025 Aug 30;62:127456. doi: 10.1016/j.vaccine.2025.127456. Epub 2025 Aug 5. Erratum in: *Vaccine*. 2025 Oct 3;64:127688. doi: 10.1016/j.vaccine.2025.127688. PMID: 40763490.
7. Feemster K, Hausdorff WP, Bannietts N, Platt H, Velentgas P, Esteves-Jaramillo A, Burton RL, Nahm MH, Buchwald UK. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. *Vaccines (Basel)*. 2024 Aug 28;12(9):974. doi: 10.3390/vaccines12090974. Erratum in: *Vaccines (Basel)*. 2025 Aug 04;13(8):831. doi: 10.3390/vaccines13080831. PMID: 39340006; PMCID: PMC11435891.
8. Scott P, Ukkonen B, Caraco Y, Perez SN, Alpizar SA, Cardona JF, Greenberg D, Grijalva CG, Orenstein W, Wiedmann RT, Fernsler D, Cheon K, Li J, Platt HL. A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4). *Med*. 2025 Oct 10;6(10):100748. doi: 10.1016/j.medj.2025.100748. Epub 2025 Jun 20. PMID: 40543503.
9. Omole T, Weinberg AS, Azizad M, Greenberg D, Grijalva CG, Orenstein WA, Euler D, Fernsler D, Park J, Li J, Platt HL; STRIDE-5 study group. A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when

- administered concomitantly with influenza vaccine in adults 50 years of age or older. *Vaccine*. 2025 Aug 30;62:127514. doi: 10.1016/j.vaccine.2025.127514. Epub 2025 Jul 25. PMID: 40714528.
10. Scott P, Haranaka M, Choi JH, Stacey H, Dionne M, Greenberg D, Grijalva CG, Orenstein WA, Fernsler D, Gallagher N, Zeng T, Li J, Platt HL; STRIDE-6 Study Group. A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older (STRIDE-6). *Clin Infect Dis*. 2024 Dec 17;79(6):1366-1374. doi: 10.1093/cid/ciae383. PMID: 39082735; PMCID: PMC11650886.
 11. Platt HL, Bruno C, Buntinx E, Pelayo E, Garcia-Huidobro D, Barranco-Santana EA, Sjoberg F, Song JY, Grijalva CG, Orenstein WA, Morgan L, Fernsler D, Xu W, Waleed M, Li J, Buchwald UK; STRIDE-3 Study Group. Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial. *Lancet Infect Dis*. 2024 Oct;24(10):1141-1150. doi: 10.1016/S1473-3099(24)00344-X. Epub 2024 Jul 1. PMID: 38964361.
 12. Flem E, Mouawad C, Palmu AA, Platt H, Johnson KD, McIntosh ED, Abadi J, Buchwald UK, Feemster K. Indirect protection in adults ≥ 18 years of age from pediatric pneumococcal vaccination: a review. *Expert Rev Vaccines*. 2024 Jan-Dec;23(1):997-1010. doi: 10.1080/14760584.2024.2416229. Epub 2024 Oct 28. PMID: 39435466.
 13. Haranaka M, Yono M, Kishino H, Igarashi R, Oshima N, Sawata M, Platt HL. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study, *Human Vaccines & Immunotherapeutics*, 2023;19:2, DOI: 10.1080/21645515.2023.2228162
 14. Dalgard O, Litwin AH, Shibolet O, Grebely J, Nahass R, Altice FL, Conway B, Gane EJ, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Haber BA, Platt H, Puenpatom A; CO-STAR Investigators. Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. *J Addict Dis*. 2023 Jul-Sep;41(3):213-224. doi: 10.1080/10550887.2022.2088978. Epub 2022 Aug 3. PMID: 35920743.
 15. Platt HL, Omole T, Cardona J, et al. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial. *Lancet ID* Available online 15 September 2022. [https://doi.org/10.1016/S1473-3099\(22\)00526-6](https://doi.org/10.1016/S1473-3099(22)00526-6)
 16. Kishino H, Sawata M, Igarashi R, et al. Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared With 13- valent Pneumococcal Vaccine

in Japanese Adults Aged ≥ 65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE) [published online ahead of print, 2022 Jul 29]. *Jpn J Infect Dis.* 2022;10. doi:10.7883/yoken.JJID.2022.060

17. Platt HL, Cardona JF, Haranaka M, et al. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). *Vaccine.* 2022;40(1):162-172. doi:10.1016/j.vaccine.2021.08.049
18. Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, Dalgard O, Gane EJ, Shibolet O, Nahass R, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Hwang P, Asante-Appiah E, Haber BA, Barr E, Robertson MN, Platt H. Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study. *Ann Intern Med.* 2022 Sep;175(9):1221-1229. doi: 10.7326/M21-4119. Epub 2022 Aug 9. PMID: 35939812.
19. Pawaskar M, Burgess C, Pillsbury M, Kanibir MN, Platt HL. Modeling Cost-Effectiveness of Universal Varicella Vaccination With Different Varicella Vaccines in the United Kingdom. *Clin Infect Dis.* 2021 Sep 7;73(5):935-936.
20. Paradis EM, Tikhonov O, Cao X, et al. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy infants, children, and adolescents. *Hum Vaccin Immunother.* 2021;17(11):4183-4189. doi:10.1080/21645515.2021.1975451
21. Paradis EM, Tikhonov O, Cao X, Kharit SM, Fokin A, Platt HL, Bannietts N. Phase 3, open-label, Russian, multicenter, single-arm trial to evaluate the immunogenicity of varicella vaccine (VARIVAX™) in healthy adults. *Hum Vaccin Immunother.* 2021 Sep 2:1-6.
22. Platt H, Tochiara S, Oda Y, Ueda K. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial. *Jpn J Infect Dis.* 2021 Sep 22;74(5):429-436. doi: 10.7883/yoken.JJID.2020.876. Epub 2021 Jan 29.
23. Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, Shekar T, Li J, Hurtado K, Su SC, Nolan KM, Acosta CJ, McFetridge RD, Bickham K, Musey LK; V114-008 Study Group. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. *Pediatr Infect Dis J.* 2020 Aug;39(8):763-770.
24. Silas PE, Zissman EN, Gardner J, Helian S, Lee AW, Platt HL. A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process

- administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II). *Hum Vaccin Immunother*. 2020 Nov 1;16(11):2634-2640.
25. Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL, C-BREEZE-2 Study Investigators. et al. Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6. *Journal of viral hepatitis*. 2019.
 26. Jacobson IM, Poordad F, Firpi-Morell R, Everson GT, Verna EC, Bhanja S, Hwang P, Caro L, Robertson M, Charles ED, Platt H. Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study. *Clinical and translational gastroenterology*. 2019.
 27. Ng X, Nwankwo C, Arduino JM, Corman S, Lasch KE, Lustrino JM, Patel S, Platt HL, Qiu J, Sperl J. Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir. *Patient Prefer Adherence*. 2018 Dec 11;12:2631-2638.
 28. Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Bräu N; Liver Cancer in HIV and ITA.LI.CA Study Groups. Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. *J Clin Oncol*. 2019 Feb 1;37(4):296-304.
 29. Zeuzem S, Serfaty L, Vierling J, Cheng W, George J, Sperl J, Strasser S, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt H. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. *J Gastroenterol*. 2018 May;53(5):679- 688.
 30. Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M, Allara E, Chen TY, Dalla Pria A, Jain M, Mínguez B, Kikuchi L, Kaufman West E, Merli M, Kaplan DE, Hasson H, Marks K, Nelson M, Núñez M, Aytaman A, Bower M, Bräu N; Liver Cancer in HIV Study Group. The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV- associated hepatocellular carcinoma. *Aliment Pharmacol Ther*. 2018 Jan;47(1):95-103.
 31. Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, Werling K, Kileng H, Koklu S, Gerstoft J, Patel S, Qiu J, Assante-Appiah E, Wahl J, Nguyen B-Y, Barr E, Platt HL. C- Edge Head-to-Head: Efficacy and Safety of Elbasvir and Grazoprevir Compared with Sofosbuvir/Pegylated Interferon/Ribavirin: A Phase 3 Randomized Controlled Trial. *J Hepatol*. 2016 Dec;65(6):1112-1119.
 32. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R,

- Peng CY, Conway B1, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. Elbasvir- Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. *Ann Intern Med*. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.
33. Moussalli J, Dore G, Platt H. COL 4-04 - C-EDGE CO-STAR: Efficacy of elbasvir and grazoprevir in persons who inject drugs receiving opioid agonist therapy. *Medecine et Maladies Infectieuses*. 2016;46(4):9. doi:10.1016/S0399-077X(16)30274-8
 34. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO- INFECTION): a non-randomised open-label trial. *Lancet HIV*. Published Online. July 10, 2016, [http://dx.doi.org/10.1016/S2352-3018\(15\)00114-9](http://dx.doi.org/10.1016/S2352-3018(15)00114-9)
 35. Gordon CL, Pouch S, Cowell LG, Boland MR, Platt HL, Goldfain A, Weng C. Design and evaluation of a bacterial clinical infectious diseases ontology. *AMIA Annu Symp Proc*. 2013 Nov 16;2013:502.11. eCollection 2013.
 36. Yavari N, Platt H, Michel R, Navarro CA, Efthimiou P. What role do occupational exposures play in RA? *J Musculoskel Med* 2008;25:130-136.
 37. Quevedo J, Purgavie K, Platt H, Strax TE. Complex regional pain syndrome: Two case reports of sphenopalatine block, a treatment option. *Arch Phys Med Rehabil* 2005;86(2):335-7.
 38. Cuccurullo S, Brown D, Petagna AM, Platt H, Strax TE. Musculoskeletal injection skills competency in physical medicine and rehabilitation residents: A method for development and assessment. *Am J Phys Med Rehab* 2004;83:479-485.

Abstracts/Posters

1. Scott PU, Pathirana JU, Kato A, Tytus R, Perez C, Gilchrist NL, Kanou H, Yoo KH, Kania G, Nissen M, Livingston M, Russell AF, Fernsler D, Waleed MU, Li JU, Buchwald UK, Platt HL. A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Investigational Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age with Increased Risk for Pneumococcal Disease. *ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE*. 2025;58:S17-S17. [Scited Link](#)
2. Scott P, Pathirana J, Kato A, Tytus R, Perez CM, Gilchrist NL, Kanou H, Ha Yoo K, Kania G, Nissen M, Livingston M, Russell AF, Fernsler D, Waleed M, Li J, Buchwald UK, Platt HL. A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Investigational Adult-Specific Pneumococcal Conjugate

Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age with Increased Risk for Pneumococcal Disease. IDWeek 2024. *Open Forum Infectious Diseases*. 2025;12:S159-S160. doi:10.1093/ofid/ofae631.252 [Scited Link](#)

3. Pathirana J, Ramgopal M, Martin C, Lombaard JJ, Chahin C, Launay O, Ratanasuwan W, Greenberg D, Grijalva CG, Orenstein WA, Shenkerman A, Fernsler D, Kim Y, Li J, Platt HL. A phase III randomized study to evaluate the safety, tolerability and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine (PCV), followed by PCV15, in adults living with HIV (STRIDE-7). *Journal of the International AIDS Society*. 2024;27:12-13. doi:10.1002/jia2.26370 [Scited Link](#)
4. Scott PU, Haranaka MU, Yang Y-C, Choi JU, Stacey HU, Dionne MU, Greenberg DU, Grijalva CGU, Orenstein WAU, Fernsler D, Gallagher N, Zeng TU, Li JU, Platt H, Romano JU. A PHASE 3 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF V116 IN PNEUMOCOCCAL VACCINE-EXPERIENCED ADULTS 50 YEARS OF AGE OR OLDER (STRIDE-6). 40th Congress of Respiratory Society, 5th LUSO-PALOP Congress and 10th Union Europe Conference On Lung Health. *Pulmonology*. 2024;30:S20. doi:10.1016/S2531-0437(24)00120-X [Scited Link](#)
5. Fernsler D, Scott PU, Gallagher N, Li JU, Zeng TU, Platt H, Romano JU. IMMUNOGENICITY OF V116 (21-VALENT PCV) IN ADULTS $\geq$ 50 YEARS OF AGE BY TIME SINCE PRIOR PNEUMOCOCCAL VACCINATION: SUBGROUP ANALYSIS OF A PHASE 3 TRIAL (STRIDE-6). 40th Congress of Respiratory Society, 5th LUSO-PALOP Congress and 10th Union Europe Conference On Lung Health. *Pulmonology*. 2024;30:S20. doi:10.1016/S2531-0437(24)00120-X [Scited Link](#)
6. Platt H, Fernsler D, Gallagher N, Sapre A, Polis A, Hall L, Tamms G, Schwartz H, Skinner J, Joyce J, Murphy R, Musey L. P08 A Phase 1, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (PCV) (V116) in adults. BSAC Winter Conference on Infection. *JAC-Antimicrobial Resistance*. 2023;5(Sp. Iss. SI):dlac133-dlac133. doi:10.1093/jacamr/dlac133.012 [Scited Link](#)
7. Omole T, Cardona J, Fraser NJ, Pagnussat S, Mularski R, Andrews C, Daboul N, Sapre A, Li J, Fernsler D, Xu W, Gallagher N, Hall L, Platt H. P09 A Phase 2, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (V116) in adults=50 years. BSAC Winter Conference on Infection. *JAC-Antimicrobial Resistance*. 2023;5(Supplement_1):dlac133-dlac133. doi:10.1093/jacamr/dlac133.013 [Scited Link](#)
8. Dalgard O, Litwin A, Dore G, Shibolet O, Grebely J, Nahass R, Altice F, Conway B, Gane E, Luetkemeyer A, Peng CY, Iser D, Gendrano IN, Kelly MM, Haber B, Platt HL, Puenpatom A. Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR. *Journal of*

Hepatology. 2020;73:S356-S356. [Scited Link](#)

9. Grebely J, Conway B, Litwin AH, Dalgard O, Shibolet O, Nahass RG, Altice F, Gane EJ, Luetkemeyer A, Peng CY, Iser D, Gendrano INI, Kelly M, Hwang P, Asante-Appiah E, Barr E, Robertson MN, Platt H, Dore G. DRUG USE AND REINFECTION DURING AND FOLLOWING HCV TREATMENT WITH ELBASVIR/GRAZOPREVRIR AMONG PATIENTS RECEIVING OPIOID AGONIST THERAPY: FINAL RESULTS FROM THE CO-STAR STUDY. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. *Hepatology*. 2019;70:955A-956A. [Scited Link](#)
10. Wei B, Kibukawa M, Chen L, Kang J, Levitan D, Asante-Appiah E, Huang H, Platt HL. Comparing a Template-independent Next-generation Sequencing Assay with Standard Genomic Assays for HCV Subtyping and Sequencing. Annual Meeting of the Association-for-Molecular-Pathology (AMP). *Journal of Molecular Diagnostics*. 2018;20(6):1016-1017. [Scited Link](#)
11. Gao W, Kandala B, Rizk M, Kim N, Platt H, Plank R, Yeh WW, Robertson M. Dose and exposure response relationship in combination therapy: A case study in HCV therapy. 9th American Conference on Pharmacometrics, ACoP 2018. *Journal of Pharmacokinetics and Pharmacodynamics*. 2018;45(S1):S114-S115. doi:10.1007/s10928-018-9606-9 [Scited Link](#)
12. Grebely J, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Conway B, Nahass R, Altice F, Luetkemeyer A, Peng CY, Iser D, Gendrano IN, Huang HC, Kelly MM, Hwang P, Barr E, Robertson MN, Platt H, Dore G. HCV Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-STAR Part B. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. *Hepatology*. 2018;68(S1):35A-35A. doi:10.1002/hep.30256 [Scited Link](#)
13. Pinato DJ, Chen T--Y, Allara E, Trevisani F, Minguez B, Zoli M, Harris M, Pria AD, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Ludovico Rapaccini G, Aytaman A, Yin M, Bower M, Giovanni Giannini E, Brau N. HIV infection adversely influences the natural history of untreated hepatocellular carcinoma (HCC). 53rd Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2018. *Journal of Hepatology*. 2018;68:S431. doi:10.1016/S0168-8278(18)31102-4 [Scited Link](#)
14. Serrano D, Nwankwo C, Platt HL, Klopfer S, Shaughnessy M, Arduino JM. Impact of treatment with Elbasvir and Grazoprevir on chronic hepatitis C virus disease specific health related quality of life outcomes in HCV/HIV coinfecting patients. 53rd Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2018. *Journal of Hepatology*. 2018;68:S282-S283. doi:10.1016/S0168-

8278(18)30782-7 [Scited Link](#)

15. Pria AD, Pinato DJ, Chen TY, Allara E, Trevisani F, Minguez B, Zoli M, Harris M, Mercahnte N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Cerrone M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Bower M, Giannini E, Brau N. HIV infection adversely influences the natural history of untreated hepatocellular carcinoma (HCC). 4th Joint Conference of the British HIV Association, BHIVA with the British Association for Sexual Health and HIV, BASHH 2018. *HIV Medicine*. 2018;19:S79-S80. [Scited Link](#)
16. Conway B, Dore GJ, Altice F, Litwin A, Grebely J, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Gendrano I, Huang H, Chen E, Nguyen B, Wahl J, Barr E, Robertson M, Platt H. C-EDGE CO-STAR: RISK of REINFECTION FOLLOWING SUCCESSFUL THERAPY with ELBASVIR (EBR) and GRAZOPREVR (GZR) in PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOID AGONIST THERAPY (OAT). Canadian Digestive Diseases Week, CDDW 2017. *Journal of the Canadian Association of Gastroenterology*. 2018;1(suppl_1):299-300. doi:10.1093/jcag/gwy008.173 [Scited Link](#)
17. Dore GJ, Grebely J, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Conway B, Nahass R, Luetkemeyer A, Peng C-Y, Iser DM, Gendrano IN, Kelly MM, Huang H-C, Hwang P, Barr E, Robertson M, Platt H. Hepatitis C virus (HCV) reinfection and injecting risk behavior following elbasvir (EBR)/grazoprevir (GZR) treatment in participants on opiate agonist therapy (OAT): Co-star part B. 68th Annual Meeting of the American Association for the Study of Liver Diseases, AASLD 2017. *Hepatology*. 2017;66:112A-113A. [Scited Link](#)
18. Lawitz E, Gane EJ, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich EZ, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson M, Hanna GJ, Barr E, Platt H. C-BREEZE 2: Efficacy and safety of a two-drug direct-acting antiviral agent (DAA) regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus (HCV) genotype (GT)1, 2, 3, 4, or 6. 68th Annual Meeting of the American Association for the Study of Liver Diseases, AASLD 2017. *Hepatology*. 2017;66:34A-35A. [Scited Link](#)
19. Zeuzem S, Serfaty L, Vierling JM, Cheng W, George J, Sperl J, Strasser SI, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt HL. High efficacy in patients with chronic hepatitis C virus genotype 1b infection treated with elbasvir-grazoprevir for 12 weeks: An integrated analysis. 2017 Gastroenterological Society of Australia, Australian Gastroenterology Week. *Journal of Gastroenterology and Hepatology (Australia)*. 2017;32(S2):81-82. doi:10.1111/jgh.13892 [Scited Link](#)
20. George J, Zeuzem S, Serfaty L, Vierling J, Cheng W, Sperl J, Strasser S, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt H. High efficacy in patients with chronic hepatitis C virus (HCV) genotype (GT)1b infection treated with elbasvir/grazoprevir (EBR/GZR) for 12 weeks: An integrated analysis. 26th Annual

Conference of the Asian Pacific Association for the Study of the Liver, APASL 2017. *Hepatology International*. 2017;11(S1):S3. doi:10.1007/s12072-016-9783-9 [Scited Link](#)

21. Gane EJ, Dore G, Grebely J, Altice F, Litwin AH, Dalgard O, Shibolet O, Luetkemeyer A, Nahass R, Peng C-Y, Conway B, Iser D, Huang H-C, Gendrano IN, Kelly M, Hwang P, Robertson M, Wahl J, Barr E, Platt H. Hepatitis C virus (HCV) reinfection and injection risk behavior following elbasvir/grazoprevir (EBR/GZR) treatment in patients on opioid agonist therapy (OAT): Co-STAR three-year follow-up study. 26th Annual Conference of the Asian Pacific Association for the Study of the Liver, APASL 2017. *Hepatology International*. 2017;11(S1):S302-S303. doi:10.1007/s12072-016-9783-9 [Scited Link](#)
22. Corman S, Jiang Y, Platt HL, Nwankwo C. Prevention of liver-related complications with elbasvir/grazoprevir in hepatitis C infected patients who are receiving opioid agonist therapy. International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver. *JOURNAL OF HEPATOLOGY*. 2017;66(1):S298-S298. [Scited Link](#)
23. Nwankwo C, King-Kallimanis B, Corman S, Qiu J, Patel S, Arduino JM, Platt HL, Sperl J. Clinically meaningful differences in health-related quality of life and fatigue in patients with hepatitis C virus infection treated with elbasvir/grazoprevir compared to sofosbuvir with pegylated interferon and ribavirin. International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver. *JOURNAL OF HEPATOLOGY*. 2017;66(1):S297-S298. doi:10.1016/S0168-8278(17)30912-1 [Scited Link](#)
24. Citti C, Pinato D, Ventura-Cots M, Platt H, Merli M, Minguez B, Pria AD, Sharma R, Marcus S, Nelson M, Bower M, Mazzaferro V, Brau N, Liver Canc Hiv Study Grp. Liver transplantation for human immunodeficiency virus-Infected patients with hepatocellular carcinoma. International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver. *JOURNAL OF HEPATOLOGY*. 2017;66(1):S216-S216. [Scited Link](#)
25. Nwankwo C, Batterson R, Todd E, Jiang Y, Platt HL, Meng Y. Projected long term impact of elbasvir/grazoprevir compared to sofosbuvir plus pegylated interferon/ribavirin in chronic hepatitis C virus genotype 1 and 4 patients in Italy: translation of the C-EDGE Head-2-Head study findings. International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver. *JOURNAL OF HEPATOLOGY*. 2017;66(1):S298-S299. [Scited Link](#)
26. Barr E, Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G, Saag MS, Zamor P, Orkin C, Gress J, Shaughnessy M, Klopfer S, Howe A, Wahl J, Nguyen BY, Robertson M, Platt HL, Sulkowski M. High efficacy of elbasvir/grazoprevir (EBR/GZR) in HCV genotype 1, 4, and 6-infected patients with HIV coinfection: SVR24 data from the phase 3 C-EDGE Coinfection study. Australian Gastroenterology Week 2016. *Journal of Gastroenterology and Hepatology (Australia)*. 2016;31(S2):66.

doi:10.1111/jgh.13519 [Scited Link](#)

27. Zeuzem S, Serfaty L, Vierling JM, Cheng W, George J, Sperl J, Strasser SI, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt HL. High efficacy in patients with chronic hepatitis C virus (HCV) Genotype (GT)1b infection treatment with elbasvir/ grazoprevir for 12 weeks: An integrated analysis. 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016. *Hepatology*. 2016;63(1):433A. [Scited Link](#)
28. Dore G, Grebely J, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng C-Y, Conway B, Iser DM, Huang H-C, Gendrano IN, Kelly MM, Hwang P, Robertson M, Wahl J, Barr E, Platt HL. HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study. 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016. *Hepatology*. 2016;63(1):431A. [Scited Link](#)
29. Dore G, Altice F, Litwin AH, Grebely J, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng C--Y, Conway B, Gendrano IN, Huang H--C, Chen E, Nguyen B--Y, Wahl J, Barr E, Robertson M, Platt HL. C-edge co-star: Risk of reinfection following successful therapy with elbasvir and grazoprevir in persons who inject drugs (PWID) receiving opioid agonist therapy (OAT). 51st Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2016. *Journal of Hepatology*. 2016;64(2):S771. [Scited Link](#)
30. Arduino JM, Shibolet O, Litwin AH, Grebeley J, Altice F, Nwankwo C, Mast TC, Jiang Z, Gendrano IN, Platt HL, Dore GJ. C-edge co-star: Favorable impact of elbasvir and grazoprevir on health-related quality of life in treatment-naïve HCV-infected persons who inject drugs receiving opioid agonist therapy. 51st Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2016. *Journal of Hepatology*. 2016;64(2):S403-S404. [Scited Link](#)
31. Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, Werling K, Kileng H, Koklu S, Gerstoft J, Patel S, Qiu J, Assante-Appiah E, Wahl J, Nguyen B--Y, Barr E, Platt HL. C-edge head-to-head: Efficacy and safety of elbasvir and grazoprevir compared with sofosbuvir/pegylated interferon/ribavirin: A phase 3 randomized controlled trial. 51st Annual Meeting of the European Association for the Study of the Liver, International Liver Congress 2016. *Journal of Hepatology*. 2016;64(2):S136-S137. [Scited Link](#)
32. Dore G, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng C-Y, Conway B, Grebely J, Howe AY, Nguyen B-Y, Wahl J, Barr E, Robertson M, Platt HL. C-edge Co-star: Efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy. 66th Annual Meeting of the American

Association for the Study of Liver Diseases: The Liver Meeting 2015. *Hepatology*. 2015;62(S1):227A-228A. doi:10.1002/hep.28172 [Scited Link](#)

33. Rockstroh JK, Nelson M, Katlama C, Lalezari JP, Mallolas J, Bloch M, Matthews G, Saag M, Zamor PJ, Orkin C, Gress J, Shaughnessy M, Klopfer S, Howe AY, Wahl J, Nguyen BYT, Barr E, Platt HL, Robertson M, Sulkowski MS. High Efficacy of Grazoprevir/Elbasvir (GZR/EBR) in HCV Genotype 1, 4, and 6-infected Patients With HIV Coinfection: SVR24 Data From the Phase 3 C-EDGE Coinfection Study. 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). *HEPATOLOGY*. 2015;62(S1):317A-317A. doi:10.1002/hep.28200 [Scited Link](#)
34. Arduino JM, Jiang Z, Shaughnessy M, Khawaja S, Martinez E, Platt HL, Nwankwo C, Mast TC. C-EDGE Co-Infection: Impact Of 12-Week Oral Regimen Of Grazoprevir (GZR, MK-5172)/Elbasvir (EBR, MK-8742) On Patient-Reported Outcomes (PROs) In Treatment-Naive Patients With HCV/HIV Co-infection. 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). *Hepatology*. 2015;62(Suppl. 1, Sp. Iss. SI):572A-573A. [Scited Link](#)
35. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G, Saag MS, Zamor P, Orkin C, Gress J, Shaughnessy M, Klopfer S, Platt HL, Robertson M, Sulkowski M. High efficacy of grazoprevir/elbasvir in HCV genotype 1, 4 and 6-infected patients with HIV co-infection: The phase 3 CEDGE co-infection study. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. *Journal of the International AIDS Society*. 2015;18(5S4):42-42. doi:10.7448/IAS.18.5.20479 [Scited Link](#)
36. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G, Saag M, Zamor P, Orkin C, Gress J, Klopfer S, Platt H, Robertson M, Sulkowski M. C-EDGE CO-INFECTED: PHASE 3 STUDY OF GRAZOPRE VIR/ELBASVIR IN PATIENTS WITH HCV/HIV. 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver. *JOURNAL OF HEPATOLOGY*. 2015;62:S675-S675. [Scited Link](#)
37. Lin L, Cuccurullo S, Petagna AM, Platt H, Strax TE. An Approach To Teaching And Evaluating Critical Appraisal Of Literature Skills In A Physical Medicine And Rehabilitation Residency Program. ACGME Project Outcome: 2002